Trial record 1 of 1 for:    Epitope | Peanut Allergy
Previous Study | Return to List | Next Study

Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age (EPITOPE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03211247
Recruitment Status : Recruiting
First Posted : July 7, 2017
Last Update Posted : November 14, 2018
Information provided by (Responsible Party):
DBV Technologies

Brief Summary:
The study aims to assess the safety and efficacy of Viaskin Peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT).

Condition or disease Intervention/treatment Phase
Peanut Allergy Biological: Viaskin Peanut 250 mcg Biological: Viaskin Peanut 100 mcg Biological: Placebo Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 331 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Double-blind, Placebo-controlled, Randomized Phase III Trial to Assess the Safety and Efficacy of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age.
Actual Study Start Date : July 31, 2017
Estimated Primary Completion Date : May 30, 2020
Estimated Study Completion Date : May 30, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Viaskin Peanut 250 mcg Biological: Viaskin Peanut 250 mcg
Viaskin Peanut 250 mcg, once daily

Experimental: Viaskin Peanut 100 mcg Biological: Viaskin Peanut 100 mcg
Viaskin Peanut 100 mcg, once daily

Placebo Comparator: Placebo Biological: Placebo
Placebo patch, once daily

Primary Outcome Measures :
  1. Differences between the percentage of treatment responders in the selected active Viaskin Peanut group compared to the placebo group. [ Time Frame: Month 12 ]

Other Outcome Measures:
  1. Adverse Events (AEs), Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) [ Time Frame: Throughout the study during 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   1 Year to 3 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Male or female from 1-3 years of age;
  • Physician-diagnosed peanut allergy;
  • Peanut-specific IgE level > 0.7 kU/L;
  • Positive peanut SPT with a largest wheal diameter ≥ 6 mm;
  • Positive DBPCFC at ≤ 300 mg peanut protein;

Key Exclusion Criteria:

  • Uncontrolled asthma;
  • History of severe anaphylaxis to peanut;
  • Prior immunotherapy to any food or other immunotherapy;
  • Generalized severe dermatologic disease;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03211247

United States, Arkansas
Arkansas Children's Hospital Recruiting
Little Rock, Arkansas, United States, 72202
Contact: Stacie M. Jones, MD    501-364-1060   
Principal Investigator: Stacie M. Jones, MD         
United States, California
Stanford University School of Medicine Active, not recruiting
Stanford, California, United States, 94305
United States, Colorado
Children's Hospital Colorado Recruiting
Aurora, Colorado, United States, 80045
Contact: David M. Fleischer, MD    720-777-2575   
Principal Investigator: David M. Fleischer, MD         
United States, Maryland
Johns Hopkins Hospital Recruiting
Baltimore, Maryland, United States, 21205
Contact: Robert Wood, MD    410-955-5883   
Principal Investigator: Robert Wood, MD         
United States, New York
Mount Sinai Medical Center Recruiting
New York, New York, United States, 10029
Contact: Julie Wang, MD    212-241-5548   
Principal Investigator: Julie Wang, MD         
United States, North Carolina
The University of North Carolina - Chapell Hill Recruiting
Chapel Hill, North Carolina, United States, 27599
Contact: Edwin Kim, MD    919-843-9087   
Principal Investigator: Edwin Kim, MD         
United States, Pennsylvania
Children's Hospital of Philadelphia Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Terri Brown-Whitehorn, MD    215-590-2549   
Principal Investigator: Terri Brown-Whitehorn, MD         
Sponsors and Collaborators
DBV Technologies

Responsible Party: DBV Technologies Identifier: NCT03211247     History of Changes
Other Study ID Numbers: EPITOPE
First Posted: July 7, 2017    Key Record Dates
Last Update Posted: November 14, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by DBV Technologies:

Additional relevant MeSH terms:
Peanut Hypersensitivity
Food Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases